Erasca and Eli Lilly announced that they have entered into a clinical trial collaboration and supply agreement for Erbitux® (cetuximab). This agreement will support Erasca’s ongoing Ph I trials evaluating ERAS-601, its SHP2 inhibitor, with cetuximab for the treatment of triple wildtype metastatic colorectal cancer and HPV-negative advanced head and neck squamous cell carcinoma. Lilly will supply cetuximab to Erasca at no cost.
Med Tech Giant Handed Largest Penalty Ever Given Under the Therapeutic Goods Act
Secretary, Department of Health v Medtronic Australasia Pty Ltd [2024] FCA 1096 Date of decision: 19 September 2024 Body: Federal Court of...